Dr. Rhonda Patrick on the Joe Rogan Experience #1178, fact-checked

What the evidence shows: A peer-reviewed study (Le et al., 2008, Toxicology Letters) measured BPA migration from polycarbonate drinking bottles and found that exposure to boiling (100°C) water increased the rate of BPA release by 15- to 55-fold compared to bottles not exposed to boiling water, with the top of that range matching Patrick's '55 fold' figure closely. The finding is specific to polycarbonate plastic bottles rather than plastics generally, so Patrick's broader phrasing ('putting it in plastic') slightly overstates the scope of the underlying research, but the core quantitative claim that heat sharply increases BPA leaching is well supported.

What the evidence shows: The figure traces to a 2014 Cell Stem Cell study from Valter Longo's lab, which found that in mice, cycles of prolonged fasting caused a 28% decrease in white blood cell count that fully reversed after refeeding, driven by increased self-renewal of hematopoietic stem cells and rebalancing of blood-cell lineages, not literal destruction and wholesale replacement of "the immune system." The same paper's human data came from a small, preliminary Phase I trial in chemotherapy patients, not healthy people doing elective 72-hour water fasts, in which 72 hours of fasting around chemotherapy (versus 24 hours) was associated with normal lymphocyte counts and lineage balance; the authors described these results as preliminary, pending confirmation in an ongoing Phase II trial. A 2023 systematic review of intermittent fasting's immunomodulatory effects found that human evidence for fasting-driven immune cell turnover remains far less developed and quantified than the animal data, with no confirmed human studies establishing a specific percentage of immune cells cleared and replenished by a 72-hour fast. The underlying mechanism (fasting-triggered hematopoietic stem cell regeneration) is real and documented in mice and in a small clinical population, but Patrick's framing (an unqualified "30%... brand-new" figure applied generally to 72-hour fasting) rounds and generalizes a rodent statistic in a way not established for healthy humans undergoing standalone 72-hour fasts.

What the evidence shows: Patrick claims that historically only about half of European sailors on vitamin C deficient diets developed scurvy while the other half showed no symptoms. No historical naval record, ship's log, or peer-reviewed source documenting a specific 50/50 split in scurvy incidence among sailors could be located. Historical accounts instead report highly variable mortality and morbidity by voyage; for example, at the 1604-1605 Saint Croix settlement 35 of 79 men (roughly 44%) died of scurvy with more than 20 others severely afflicted, a very different ratio than the claimed even split. Modern clinical literature does support that individual response to vitamin C deficiency varies, including documented differences in how quickly deficiency symptoms appear (roughly 40 days in some controlled studies versus 161 days in one case), and that symptom presentation can be partial or missed on initial diagnosis. However, this variability in onset and presentation is not equivalent to, and does not establish, a specific historical rate of half of deficient sailors being fully asymptomatic. The specific 50% figure Patrick cites is best classified as an approximation not tied to any identifiable historical dataset.

What the evidence shows: Patrick appears to be referencing Cipolla et al. (2015), a double-blind, randomized, placebo-controlled trial of 78 men with rising PSA after radical prostatectomy who received 60 mg/day of stabilized sulforaphane or placebo for six months. The trial did report that PSA doubling time was 86% longer in the sulforaphane group than placebo (28.9 vs. 15.5 months), so the 86% figure itself is accurate to a real published result. However, PSA doubling time was a secondary outcome; the trial's pre-specified primary endpoint (change in log PSA slope from baseline to month 6) was not met. PSA doubling time is a surrogate biomarker, not a measure of cancer recurrence, metastasis, or survival. A 2023 systematic review of randomized controlled trials on sulforaphane in cancer found that results on PSA-related outcomes across the small number of available prostate cancer trials were inconsistent, that 75% of included trials carried a high risk of bias, and concluded that large-scale, robust trials are needed before clinical recommendations can be made. A separate small single-arm phase II trial of a different sulforaphane-rich extract (20 patients) found a smaller, though still statistically significant, lengthening of PSA doubling time (6.1 to 9.6 months).

What the evidence shows: Dr. Dale Bredesen has published case series, most notably a 2014 report of 10 patients, claiming cognitive improvement or reversal using a multi-component "MEND"/ReCODE lifestyle and supplement program. That original study was an uncontrolled case series with no comparison group, and the authors themselves stated a larger, controlled trial was needed to validate the findings. A UCSF neurologist's published review of Bredesen's papers found the studies lacked placebo controls, omitted key methodological details (protocol procedures, participant criteria, information on non-responders), appeared in low-oversight open-access journals, and had at least one undisclosed financial conflict of interest; the reviewer concluded there is no evidence that the intensive, costly regimen reverses or prevents Alzheimer's disease beyond standard, already-recommended measures like exercise and a Mediterranean diet. As of mid-2026, no large, blinded, placebo-controlled trial has confirmed disease reversal, and mainstream Alzheimer's specialists do not accept that the protocol reverses the underlying disease. The evidentiary basis for Patrick's claim is small uncontrolled case series, not confirmed reversal of Alzheimer's disease.

What the evidence shows: The trial design Patrick describes, 4 grams/day of EPA (icosapent ethyl) given to 8,179 statin-treated patients with elevated triglycerides across multiple countries, with a median follow-up of 4.9 years and a 25% relative risk reduction in the primary cardiovascular composite endpoint (17.2% vs 22.0%, HR 0.75), matches the REDUCE-IT trial, published in the New England Journal of Medicine in 2019, not the VITAL study. The actual VITAL trial tested a much lower dose, 1 gram/day of mixed EPA/DHA fish oil, in 25,871 generally healthy US adults not selected for elevated triglycerides or statin use, over a median 5.3 years, and found no statistically significant reduction in the composite major cardiovascular event endpoint (hazard ratio 0.92, 95% CI 0.80-1.06, p=0.24), though it did find a reduction in total myocardial infarction specifically. Patrick's reported risk-reduction figure of 28-30% and the described patient population do not match VITAL's null primary result. The dose, patient count, and duration she cites correspond closely to REDUCE-IT rather than VITAL, indicating the trial name and outcome were conflated between the two studies.